Comparative Pharmacology
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus TIROSINT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus TIROSINT.
LIOTHYRONINE SODIUM vs TIROSINT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liothyronine is a synthetic form of triiodothyronine (T3), the active thyroid hormone. It binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing basal metabolic rate, oxygen consumption, and thermogenesis. It enhances carbohydrate and lipid metabolism, and promotes normal growth and development.
Tirosint is a synthetic form of levothyroxine (T4), which is converted to triiodothyronine (T3) in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription to increase metabolic rate, protein synthesis, and oxygen consumption.
25-75 mcg orally once daily; initial dose 25 mcg daily, titrate by 12.5-25 mcg increments every 1-2 weeks based on response.
Initial dose 1.6 mcg/kg orally once daily, adjusted based on TSH levels. Typical maintenance dose 50-200 mcg/day.
None Documented
None Documented
Approximately 1-2 days in euthyroid patients; shorter in hyperthyroidism, prolonged in hypothyroidism. Clinical context: requires monitoring of thyroid function tests for dose adjustment.
Terminal half-life approximately 7 days in euthyroid individuals; prolonged in hypothyroidism (up to 9-10 days) and shortened in hyperthyroidism (3-4 days). Clinical context: steady-state reached in 4-6 weeks; dosage adjustments require 6-8 weeks for full effect.
Primarily renal (approximately 50% as unchanged drug and metabolites); minor biliary/fecal elimination.
Renal (approximately 30-40% as unchanged drug and metabolites, primarily glucuronide and sulfate conjugates); fecal (approximately 20-30% via bile); total clearance is low (~0.05 L/hr/kg).
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone